Vaxart was served a grand ju­ry sub­poe­na in Ju­ly over its con­tro­ver­sial role in OWS-fund­ed pre­clin­i­cal study

One-time pen­ny stock play­er Vaxart made mar­ket waves Tues­day morn­ing when the com­pa­ny an­nounced it had dosed the first pa­tients in the Phase I study for its oral Covid-19 vac­cine can­di­date. But un­der­neath those head­lines came an­oth­er piece of news: a grand ju­ry sub­poe­na.

In an 8-K fil­ing with the SEC on Wednes­day, Vaxart re­vealed the US At­tor­ney’s Of­fice for the North­ern Dis­trict of Cal­i­for­nia served the com­pa­ny with the sub­poe­na back in Ju­ly. The gov­ern­ment is prob­ing Vaxart’s par­tic­i­pa­tion in a study fund­ed by Op­er­a­tion Warp Speed and the com­pa­ny’s dis­clo­sure of the news, as well as grants, war­rant trans­ac­tions, and oth­er fi­nanc­ing mat­ters be­gin­ning in March 2020, ac­cord­ing to the fil­ing.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.